article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
List view / Grid view
Johnson & Johnson
news
DRC to use a second Ebola vaccine by November
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
news
Drugmakers may use Purdue’s bankruptcy to settle opioid suits
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
news
Endo and Allergan settle opioid case ahead of trial
The two pharma companies have agreed to pay $15 million to certain Ohio counties before an opioid abuse trial to be held in October.
news
Drug makers file complaint for regulations to lower Canadian drug prices
Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
news
Imbruvica® granted expanded use from European Commission
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
article
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
news
FTC investigates contracts regarding autoimmune disease drug, Remicade
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
news
DRC rejects clinical trial for experimental Ebola vaccine
The health minister for the Democratic Republic of the Congo has stated an experimental Ebola vaccine will not be trialled in the country.
news
Controlled release drug delivery market to rise 14.3 percent
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
news
Ten big pharma companies collaborate on data sharing AI
A new AI project marks the first time 10 pharmaceutical companies have agreed to share data to aid drug discovery.
article
It’s not just about the science: microbiological analysis
Modernisation of microbiological test methods involves far more than just the science. As new systems and technologies become available it becomes increasingly important that potential users can identify not only the technical requirements, but also the business case. Here, Paul Newby, Alice Laures and Lisa Wysocki from GlaxoSmithKline discuss criteria…
news
Biotechnology/pharmaceutical services outsourcing market worth $92.9bn by 2025
The global biotechnology services outsourcing market is expected to reach USD 92.9 billion by 2025, according to a report by Grand View Research, Inc...
article
Joining the dots at Janssen
As part of EPR’s Women in Pharma series, Catherine Owen, President of Infectious Disease and Vaccines at Johnson & Johnson, talks to Science Editor Dr Zara Kassam about keeping up with the competition, innovation and grasping the breadth of business...
news
Experimental treatment for Niemann-Pick disease appears safe
An experimental drug has appeared to slow the progression of Niemann-Pick disease type C1...
